LATEST SELECT TO FILTER LATEST BY CATEGORY Articles Case Studies News & Press FEATUREDNEWS & PRESS RiverVest Venture Partners Closes $275 Million Life Sciences Fund READ MORE PREVIOUS NEXT PORTFOLIO COMPANIES IN THE NEWS Biolinq raises $100 million for needle-free biosensors for diabetes monitoring – 11/2/2021 Xilio Therapeutics Announces Closing of Initial Public Offering – 10/26/2021 U.S. FDA Approves LIVMARLI (Maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older – 9/29/2021 Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors – 9/16/2021 Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia – 9/9/2021 Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality – 8/17/2021 Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates – 8/10/2021 Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results – 8/9/2021 Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update – 8/5/2021 SeQure Dx Announces $17.5M Series A Funding – 8/3/2021 Mirum Pharmaceuticals And GC Pharma Enter Into Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea – 7/26/2021 Wugen Raises $172 Million to Advance Clinical State Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials – 7/15/2021 Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System – 06/29/2021 Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients – 6/29/2021 Mirum Pharmaceuticals Presents Analyses From Its Rare Disease Programs at the EASL International Liver Congress 2021 – 6/23/2021 Spruce Biosciences Announces Publication Of Phase 2 Results For Tildacerfont In Journal Of Clinical Endocrinology And Metabolism – 6/21/2021 Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors – 6/17/2021 Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy – 6/1/2021 Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology – 5/24/2021 New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms – 5/24/2021 Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology – 5/22/2021 Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results – 5/20/2021 Sparrow Pharmaceuticals Secures $50 Million Series A Financing – 5/18/2021 Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates – 5/12/2021 Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium – 5/12/2021 OncoResponse Appoints Chris Russell as Chief Financial Officer – 5/11/2021 Allakos Reports First Quarter 2021 Financial Results and Provides Business Update – 5/10/2021 Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update – 5/6/2021 Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance – 5/4/2021 Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases – 4/29/2021 Pfizer Acquires Amplyx Pharmaceuticals – 4/28/2021 Arch Oncology Secures $105 Million Series C Financing – 4/27/2021 Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome – 4/26/2021 Wugen Appoints Daniel Kemp Ph.D., as Chief Executive Officer – 4/14/2021 St. Louis 101 S. Hanley Road, Suite 1850 St. Louis, MO 63105 Phone: (314) 726.6700 MAP & PARKING DIRECTIONS San Diego 10996 Torreyana Road, Suite 280 San Diego, CA 92121 Phone: (314) 726.6700 MAP & PARKING DIRECTIONS Cleveland 11000 Cedar Avenue Cleveland, OH 44106 Phone: (216) 658.3982 MAP & PARKING DIRECTIONS RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation. Contact us at info@rivervest.com Subscribe to our Newsletter © Copyright 2021 RiverVest® All Rights Reserved. By continuing to browse the site, you are agreeing to our use of cookies. OK LEARN MORE